GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Phase 2

Aleniglipron

GSBR-1290

Company
Structure Therapeutics
Mechanism
mono GLP-1
Route
Oral
Recruiting trials
2 recruiting
15.2% Placebo-adjusted weight loss · 36 weeks · Adults with obesity or overweight · Phase 2b obesity trial (high dose)

Next milestone: Phase 3 initiation (2026-H2, estimated)

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Aleniglipron and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07654361

    Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 3600 participants Est. completion 2028-11 71 sites Stand-alone
    Other conditions: Obesity, Overweight, Chronic Weight Management
    View official trial listing →
  • Recruiting NCT NCT07654374

    A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 1100 participants Est. completion 2028-11 74 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight, Chronic Weight Management
    View official trial listing →
  • Completed NCT NCT05762471

    Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 142 participants Est. completion 2024-04-11 4 sites Stand-alone
    Type 2 diabetes Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT05893043

    A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 18 participants Est. completion 2023-06-28 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Status unknown NCT NCT06139055

    A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 70 participants Est. completion 2024-03 3 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT06693843

    A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 230 participants Est. completion 2026-07-09 39 sites Stand-alone
    Other conditions: Obesity, Overweight, or Chronic Weight Management
    View official trial listing →
  • Completed NCT NCT06703021

    A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 85 participants Est. completion 2026-01-12 10 sites Stand-alone
    Other conditions: Obesity, Overweight, Chronic Weight Management
    View official trial listing →
  • Active, not recruiting NCT NCT07169942

    Aleniglipron Phase 2 Body Composition Study

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 71 participants Est. completion 2026-10 11 sites Stand-alone
    Other conditions: Obesity, Overweight, or Chronic Weight Management
    View official trial listing →
  • Active, not recruiting NCT NCT07400588

    Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

    Not yet reported Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 58 participants Est. completion 2026-09 16 sites Stand-alone
    Type 2 diabetes Other conditions: Obese, Obesity, Weight Loss
    View official trial listing →
Efficacy history
15.2%

Placebo-adjusted weight loss · 36 weeks

Adults with obesity or overweight

Trial: Phase 2b obesity trial (high dose) (Phase 2)

Source →

Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.

Safety

Reported nausea rates were higher than several competing oral GLP-1 candidates in cross-trial reporting; not derived from a head-to-head study.

Source →
Sources

Also known as: Aleniglipron, GSBR-1290

Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.